Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiyao Gu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Hematology & Oncology|November 10, 2020
Emerging agents and regimens for multiple myelomaYang Yang, Yi Li, Huiyao Gu, et al.
Journal of Materials Chemistry. B|February 6, 2023
Calcium silicate/bortezomib combinatory therapy for multiple myelomaLiqin Cao, Huiyao Gu, Zhaowenbing Zhang, et al.
Biomarker Research|January 7, 2021
Metabolic reprogramming in macrophage responsesYang Liu, Ruyi Xu, Huiyao Gu, et al.
Cancer Immunology, Immunotherapy : CII|July 26, 2022
Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myelomaHaimeng Yan, Donghua He, Jianwei Qu, et al.
International Journal of Cancer|August 8, 2019
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myelomaXi Huang, Huiyao Gu, Enfan Zhang, et al.
Clinical Epigenetics|July 7, 2022
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expressionLiqin Cao, Qingxiao Chen, Huiyao Gu, et al.
Oxidative Medicine and Cellular Longevity|September 4, 2020
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/<i>β</i>-Catenin Signaling PathwaysXiuhua Wu, Yang Liu, Enfan Zhang, et al.
Oncoimmunology|April 4, 2022
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axisYang Liu, Haimeng Yan, Huiyao Gu, et al.
Oncogene|November 11, 2021
RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathwaysJianwei Qu, Yifan Hou, Qingxiao Chen, et al.
Haematologica|May 19, 2018
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone diseaseJingsong He, Qingxiao Chen, Huiyao Gu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Hematology & Oncology|November 10, 2020
Emerging agents and regimens for multiple myelomaYang Yang, Yi Li, Huiyao Gu, et al.
Journal of Materials Chemistry. B|February 6, 2023
Calcium silicate/bortezomib combinatory therapy for multiple myelomaLiqin Cao, Huiyao Gu, Zhaowenbing Zhang, et al.
Biomarker Research|January 7, 2021
Metabolic reprogramming in macrophage responsesYang Liu, Ruyi Xu, Huiyao Gu, et al.
Cancer Immunology, Immunotherapy : CII|July 26, 2022
Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myelomaHaimeng Yan, Donghua He, Jianwei Qu, et al.
International Journal of Cancer|August 8, 2019
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myelomaXi Huang, Huiyao Gu, Enfan Zhang, et al.
Clinical Epigenetics|July 7, 2022
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expressionLiqin Cao, Qingxiao Chen, Huiyao Gu, et al.
Oxidative Medicine and Cellular Longevity|September 4, 2020
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/<i>β</i>-Catenin Signaling PathwaysXiuhua Wu, Yang Liu, Enfan Zhang, et al.
Oncoimmunology|April 4, 2022
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axisYang Liu, Haimeng Yan, Huiyao Gu, et al.
Oncogene|November 11, 2021
RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathwaysJianwei Qu, Yifan Hou, Qingxiao Chen, et al.
Haematologica|May 19, 2018
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone diseaseJingsong He, Qingxiao Chen, Huiyao Gu, et al.
Pageof 2